Canlyniadau Chwilio - Jon Curwen
- Dangos 1 - 10 canlyniadau o 10
-
1
Role of the endothelin axis and its antagonists in the treatment of cancer gan Anna Bagnato, Marilena Loizidou, B R Pflug, Jon Curwen, J Growcott
Cyhoeddwyd 2011Revisão -
2
-
3
Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the... gan Jon Curwen, Helen Musgrove, Jane Kendrew, Graham H.P. Richmond, Donald Ogilvie, Stephen R. Wedge
Cyhoeddwyd 2008Artigo -
4
In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib gan Michael G. Rolf, Jon Curwen, Margaret H. Veldman-Jones, Cath Eberlein, Jianyan Wang, Alex Harmer, Caroline J. Hellawell, Martin Braddock
Cyhoeddwyd 2015Artigo -
5
The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation gan Matthew Skinner, Karen Philp, David Lengel, Lucy C. Coverley, Eva Lamm Bergström, Philip Glaves, Helen Musgrove, Helen Prior, Martin Braddock, R. Huby, Jon Curwen, Paul Duffy, Alexander R. Harmer
Cyhoeddwyd 2013Artigo -
6
Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer gan Chrysiis Michaloglou, Claire Crafter, Rasmus Siersbæk, Oona Delpuech, Jon Curwen, Larissa S. Carnevalli, Anna D. Staniszewska, Urszula M. Polanska, Azadeh Cheraghchi-Bashi, Mandy Lawson, Igor Chernukhin, Robert McEwen, Jason S. Carroll, Sabina Cosulich
Cyhoeddwyd 2018Artigo -
7
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules gan Sylvie M. Guichard, Jon Curwen, Teeru Bihani, Celina M. D’Cruz, James Yates, Michael Grondine, Zoë Howard, Barry R. Davies, Graham Bigley, Teresa Klinowska, Kurt G. Pike, Martin Pass, Christine M. Chresta, Urszula M. Polanska, Robert McEwen, Oona Delpuech, Stephen Green, Sabina Cosulich
Cyhoeddwyd 2015Artigo -
8
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530 gan Tim P. Green, Mike Fennell, Robin Whittaker, Jon Curwen, Vivien N. Jacobs, J M Allen, Armelle Logié, Judith Hargreaves, D. Mark Hickinson, Robert W. Wilkinson, Paul Elvin, Brigitte Boyer, Neil O. Carragher, Patrick A. Plé, Alun Bermingham, Geoffrey A. Holdgate, Walter H.J. Ward, Laurent Hennequin, Barry R. Davies, Gerard Costello
Cyhoeddwyd 2009Artigo -
9
AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer gan Stephen R. Wedge, Jane Kendrew, Laurent Hennequin, Paula J. Valentine, Simon T. Barry, Sandra R. Brave, Neil R. Smith, Neil H. James, Michael Dukes, Jon Curwen, Rosemary Chester, Janet A. Jackson, Sarah J. Boffey, Lyndsey L. Kilburn, Sharon Barnett, Graham H.P. Richmond, P.F. Wadsworth, Mike Walker, Alison Bigley, Sian Taylor, Lee Cooper, Sarah Beck, Juliane M. Jürgensmeier, Donald Ogilvie
Cyhoeddwyd 2005Artigo -
10
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and<i>ESR1</i>-Mutant Breast Tumors in Preclinical Models gan Hazel M. Weir, Robert H. Bradbury, Mandy Lawson, Alfred A. Rabow, David Buttar, Rowena Callis, Jon Curwen, Camila de Almeida, Peter Ballard, Michael Hulse, Craig S. Donald, Lyman J. Feron, Galith Karoutchi, Philip A. MacFaul, Tom Moss, Richard A. Norman, Stuart E. Pearson, Michael Tonge, Gareth M. Davies, Graeme E. Walker, Zena Wilson, Rachel Rowlinson, Steve Powell, C Sadler, Graham H.P. Richmond, Brendon Ladd, Ermira Pazolli, Anne Marie Mazzola, Celina M. D’Cruz, Chris De Savi
Cyhoeddwyd 2016Artigo
Offerynnau Chwilio:
Pynciau Perthynol
Pharmacology
Biology
Medicine
Cancer research
Internal medicine
Cancer
Receptor
Endocrinology
Angiogenesis
Breast cancer
Cell biology
Estrogen receptor
Bioinformatics
Biotechnology
Endothelin receptor
Fulvestrant
Genetics
In vivo
PI3K/AKT/mTOR pathway
Signal transduction
Tyrosine kinase
VEGF receptors
Vascular endothelial growth factor
mTORC1
ACE inhibitor
Alternative medicine
Angiotensin-converting enzyme
Antagonist
Biochemistry
Blockade